BlackRock Fund Advisors’s Mateon Therapeutics, Inc. MATN Stock Holding History

BlackRock Fund Advisors’s Portfolio MATN Stock Details MATN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,839	Closed	-$4K	–	4273
2016 Q3	$4K	Buy	6,839 +747	+12%	+$506	﹤0.01%	4120
2016 Q2	$4K	Buy	+6,092	New	+$4.32K	﹤0.01%	4150

Other funds holding MATN

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

BlackRock Fund Advisors's MATN Position: Q4 2016 in Review

BlackRock Fund Advisors sold out of Mateon Therapeutics, Inc. (MATN) in Q4 2016, closing a stake of 6,839 shares — an estimated $4K sold.

BlackRock Fund Advisors first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $4K in Q3 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.

BlackRock Fund Advisors reported no remaining Mateon Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
BlackRock Fund Advisors sold 6,839 Mateon Therapeutics, Inc. shares in Q4 2016, an estimated $4K.
BlackRock Fund Advisors first reported a position in Mateon Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
BlackRock Fund Advisors's Mateon Therapeutics, Inc. position peaked at $4K in Q3 2016.
1 fund tracked by Wall St. Rank held Mateon Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.